Evaluation with E-test of the meropenem/vaborbactam association in carbapenem-resistant and sensitive negative control strains isolates of samples processed at the Laboratory of the Rivoli Hospital
https://doi.org/10.4081/mm.2022.10405
HTML: 16
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Background and aims: Meropenem (Mer) and vaborbactam (Vab) is a combination of a carbapenem and a new β-lactamase inhibitor used in adults to treat different types of infections caused by Gram-negative bacteria. This combination is chosen as an alternative in infections caused by Gram-negative bacteria when carbapenem-only therapies are unsatisfactory.
Materials and methods: Based on this, we report our assessment of such meropenem/vaborbactam association through the E-test and the Microscan routine automated system. This evaluation was performed on 22 samples, carbapenem-resistant strains of Gram-negative bacteria isolated from different types of biological material. Five E. coli and 1 P. mirabilis were respectively susceptible to both carbapenems and Mer/Vab, 6 P. aeruginosa and 2 A. baumannii were respectively resistant to both carbapenems and Mer/Vab and out of 8 K. pneumoniae which were resistant to carbapenems only one was resistant to the Mer/Var combination.
Results and conclusions: From the data obtained, it can be seen that resistance to carbapenems is 72%, and drops to 36% with the combined use of Mer/Vab. However, this combination cannot be used in the treatment of patients with diseases caused by P. aeruginosa and Acinetobacter spp., resistant to meropenem.
Bradley N., Lee Y. Practical Implications of New Antibiotic Agents for the Treatment of Carbapenem-Resistant Enterobacteriaceae. Microbiol Insights 2019;12:e-Collection 2019. DOI: https://doi.org/10.1177/1178636119840367
Dhillon S. Meropenem/vaborbactam: A Review in Complicated Urinary Tract Infections. Drugs 2018;78:1259-1270. DOI: https://doi.org/10.1007/s40265-018-0966-7
European Medicines Agency. Vabomere (meropenem / vaborbactam) 657766/2018. Available at: https://www.ema.europa.eu/en/documents/overview/vabomere-epar-medicine-overview_it.pdf (last access on January the 11th, 2022).
Johnston BD, Thuras P, Porter SB, et al. Activity of meropenem/vaborbactam against international carbapenem-resistant Escherichia coli isolates in relation to clonal background, resistance genes, resistance to comparators and region. J Glob Antimicrob Resist 2021;24:190-197. DOI: https://doi.org/10.1016/j.jgar.2020.12.017
Kinn PM, Chen DJ, Chiring DM, et al. In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance. Diagn Microbiol Infect Dis. 2019;93:258-260. DOI: https://doi.org/10.1016/j.diagmicrobio.2018.09.017
Kufel WD, Eranki AP, Paolino KM, et al. In vivo pharmacokinetic analysis of meropenem/vaborbactam during continuous venovenous haemodialysis. J Antimicrob Chemother 2019;7:2117-2118. DOI: https://doi.org/10.1093/jac/dkz103
Parisio EM. [Le nuove molecole antibiotiche per il trattamento delle infezioni da batteri gram-negativi.][Article in Italian.] Infection Control. October the 25th, 2021. Azienda USL Toscana Nord Ovest, Italy.
Vaccaro E. [Polmoniti e altre infezioni da batteri Gram negativi, il corretto place in therapy dei nuovi farmaci.][Article in Italian.] #SIMIT2020. January the 13th, 2021.
Supporting Agencies
NonePAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
